{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-204056","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.963616+00:00","generated_at":"2026-05-14T23:59:11.173244+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago","bullets":["Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.","Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.","Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.","Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.","Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-204056","json":"https://secwatch.observer/filing/0001193125-26-204056.json","markdown":"https://secwatch.observer/filing/0001193125-26-204056.md","text":"https://secwatch.observer/filing/0001193125-26-204056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/d132166d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:59:11.173244+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45e5105f4a4961b5b7afe3ae9270a9cf5e776197","claim":"Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.","evidence_excerpt":"Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$18.5 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}